WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522371
CAS#: 920509-32-6
Description: Resmetirom, also known as MGL-3196, is a potent and highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor β (THR-β) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor α (THR-α).
MedKoo Cat#: 522371
Name: Resmetirom
CAS#: 920509-32-6
Chemical Formula: C17H12Cl2N6O4
Exact Mass: 434.02971
Molecular Weight: 435.22
Elemental Analysis: C, 46.92; H, 2.78; Cl, 16.29; N, 19.31; O, 14.70
Resmetirom, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 500mg may be 2 weeks.
Synonym: MGL-3196; MGL 3196; MGL3196; VIA 3196; VIA3196; VIA-3196; Resmetirom.
IUPAC/Chemical Name: 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
InChi Key: FDBYIYFVSAHJLY-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
SMILES Code: N#CC1=NN(C2=CC(Cl)=C(OC(C=C3C(C)C)=NNC3=O)C(Cl)=C2)C(NC1=O)=O
The following data is based on the product molecular weight 435.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N,
Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y,
Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J. Discovery of
2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio
xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly
Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment
of dyslipidemia. J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299.
Epub 2014 Apr 8. PubMed PMID: 24712661.
2: Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif
JC. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196,
a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis. 2013
Oct;230(2):373-80. doi: 10.1016/j.atherosclerosis.2013.07.056. Epub 2013 Aug 21.
PubMed PMID: 24075770.
Resmetirom, or MGL-3196, shows outstanding safety in a rat heart model and is efficacious in a preclinical model at doses that showed no impact on the central thyroid axis.
